PTLD: Difference between revisions
CSV import Tag: Reverted |
No edit summary Tag: Manual revert |
||
| Line 33: | Line 33: | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | {{No image}} | ||
Latest revision as of 18:41, 18 March 2025
PTLD or Post-transplant lymphoproliferative disorder is a complication that can occur after an organ transplant. It is a condition characterized by the rapid growth and proliferation of cells of the lymph system. This is often as a result of immunosuppression, a necessary treatment to prevent organ rejection in transplant patients.
Epidemiology[edit]
PTLD is most common in recipients of heart, lung, and intestinal transplants, with a prevalence of 2-10% in adults and 2-20% in children. The risk of developing PTLD is highest in the first year after transplantation.
Pathophysiology[edit]
The pathophysiology of PTLD is complex and multifactorial. It is primarily driven by the Epstein-Barr virus (EBV), which infects B cells and can lead to their uncontrolled proliferation. Immunosuppressive therapy, which is necessary to prevent organ rejection, further contributes to the development of PTLD by impairing the immune system's ability to control EBV infection.
Clinical Presentation[edit]
The clinical presentation of PTLD is highly variable and can range from benign, self-limiting mononucleosis-like illness to aggressive non-Hodgkin lymphoma. Symptoms can include fever, weight loss, and organ dysfunction.
Diagnosis[edit]
Diagnosis of PTLD involves a combination of clinical, radiological, and pathological evaluation. Biopsy of the affected organ or lymph node is often necessary to confirm the diagnosis.
Treatment[edit]
Treatment of PTLD involves reducing immunosuppression, antiviral therapy, and in some cases, chemotherapy or monoclonal antibody therapy.
Prognosis[edit]
The prognosis of PTLD is variable and depends on several factors, including the type of PTLD, the organ transplanted, and the patient's response to treatment.
